KCT0009699
Recruiting
未知
A multi-center, randomized, assessor-blind, superiority, confirmatory clinical trial to assess safety and efficacy of cognitive therapy software ‘NDTx-01’ for improving social awareness and interaction in children and adolescents with Autism Spectrum Disorder (ASD) or Social Communication Disorder (SCD)
eudive Inc.0 sites80 target enrollmentTBD
ConditionsMental and behavioural disorders
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Mental and behavioural disorders
- Sponsor
- eudive Inc.
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Children and adolescents between the ages of 10 and 18
- •Diagnosed with autism spectrum disorder (ASD) or social communication disorder (SCD) based on the clinical judgment of a psychiatrist according to DSM\-5 diagnostic criteria
- •Participants who are able to install ‘NDTx\-01’ on an Android smartphone and use it alone or with the help of their guardian
- •Participants who are able to comply with the recommended application time for the investigational medical device (6 weeks, 30 times, 5 times a week)
- •Participants who have agreed not to use any other medical devices besides the investigational medical device during the clinical trial
- •Participants who agree that there should be no change in the use of drugs which can significantly affect one’s sociality during the clinical trial (If there is a drug being taken during screening, it can be taken continuously, but the total daily dose, ingredients, etc., should remain unchanged until the end of the study visit.)
- •Participants who agree not to participate in other Applied Behavior Analysis (ABA) treatment/rehabilitation/education, social treatment/rehabilitation/education program (If there is treatment/rehabilitation/education being received during screening, it can be received continuously, but the number of applications and treatment methods should remain unchanged until the end of the study visit.)
- •Participants who and whose parents (legal guardians) have volunteered to participate in this clinical trial and have given written consent to the subject description and consent form
- •Participants willing to comply with the clinical trial procedures
Exclusion Criteria
- •A risk of clinically significant behavioral problems, emotion regulation problems, psychotic symptoms, self\-harm, or other harm at a level that affects the treatment process
- •Severe acute/chronic medical or mental illness
- •Serious trauma or surgery performed within 4 weeks before the screening date
- •Participants with other disabilities such as severe neurological diseases (e.g. brain lesions, mental disorders, etc.)
- •Participants who are currently participating in another clinical trial or have participated in another clinical trial within 30 days before the screening date
- •Participants with a previous history of using NDTx\-01, the investigational device
- •Participants who have a change in the usage or dosage of drugs which can significantly affect one’s sociality, or a change in participation in treatment/rehabilitation/education programs that can significantly affect one’s sociality within 8 weeks before the baseline date of the clinical trial
- •In other cases where the investigator determines that participation in the clinical trial is inappropriate due to ethical reasons or the possibility of influencing the results of the clinical trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A randomized, assessor-blinded, multicenter, international study investigating efficacy, patient's acceptance, safety and tolerability of Sodium Phosphate tablets compared to split dose Polyethylene Glycol for colon cleansing prior to colonoscopy.EUCTR2012-005115-13-ESABORATOIRES MAYOLY SPINDLER448
Recruiting
Not Applicable
A multicentre, assessor-blinded, randomized controlled trial to investigate the effectiveness of a blended intervention, focused on personal feedback and coaching regarding physical activity and protein intake, after discharge in patients who have undergone elective gastro-intestinal or lung cancer surgeryNL-OMON51948Vrije Universiteit Medisch Centrum161
Recruiting
Not Applicable
Optimal Physical Recovery After HospitalizatioNL-OMON24920Amsterdam Movement Sciences, Cancer Center Amsterdam161
Active, not recruiting
Not Applicable
A multi-center, randomized, evaluator-blind, parallel group study evaluation of the efficacy, safety, and tolerability of DUAC® Akne Gel and Epiduo® Gel in the topical treatment of facial acne vulgarisacne vulgarisMedDRA version: 9.1Level: LLTClassification code 10000519Term: Acne vulgarisEUCTR2008-002359-26-DEStiefel Laboratories
Completed
Phase 3
A Phase III clinical trial of Teriparatide in postmenopausal women with osteoporosisCTRI/2021/04/032769Intas Pharmaceuticals Ltd